Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa (AMPECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02494570
Recruitment Status : Completed
First Posted : July 10, 2015
Last Update Posted : May 3, 2022
Information provided by (Responsible Party):
Aadi Bioscience, Inc.

Brief Summary:

A phase 2 multi-center investigation of efficacy of ABI-009 (nab-sirolimus) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).

Funding Source - FDA OOPD

Condition or disease Intervention/treatment Phase
PEComa Drug: ABI-009 Phase 2

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Study Start Date : October 2015
Actual Primary Completion Date : November 2021
Actual Study Completion Date : April 2022

Arm Intervention/treatment
Experimental: ABI-009 Drug: ABI-009

Primary Outcome Measures :
  1. objective response rate [ Time Frame: up to 32 months ]

Secondary Outcome Measures :
  1. Duration of response [ Time Frame: From Initial response until tumor progression, up to 32 months ]
  2. Progression free rate at 6 months [ Time Frame: 6 months ]
  3. Progression free survival [ Time Frame: from start of treatment to first documented disease progression, up to 32 months ]
  4. Overall survival [ Time Frame: From start of treatment to date of death (of any cause), up to 32 months ]
  5. Number of participants with Adverse events [ Time Frame: up to 32 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a histologically confirmed diagnosis of malignant PEComa that is either metastatic or locally advanced and for which surgery is not a recommended option.
  2. Patients must have available tumor block along with the corresponding pathology report (or approximately 30 unstained slides, with a minimum of 16 slides), and/or fresh biopsy to allow retrospective centralized confirmation of malignant PEComa and for mTOR pathway analysis and biomarker analysis.
  3. Patients must have one or more measurable target lesions by CT scan or MRI. Measurable disease by RECIST v1.1.
  4. Patients must not have been previously treated with an mTOR inhibitor.
  5. Prior treatment (investigational or other), chemotherapy, radiotherapy, surgery, or other therapeutic agents (except mTOR inhibitors) is allowed, if completed after 5 half-lives or ≥28 days prior to enrollment, whichever is shorter.
  6. Eligible patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Patients must have the following blood chemistry levels at screening (obtained

    ≤14 days prior to enrollment (local laboratory):

    1. total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dl
    2. AST ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases)
    3. serum creatinine ≤1.5 x ULN
  8. Adequate biological parameters as demonstrated by the following blood counts at screening (obtained ≤14 days prior to enrollment, local laboratory):

    1. Absolute neutrophil count (ANC) ≥1.5 × 109/L;
    2. Platelet count ≥100,000/mm3 (100 × 109/L);
    3. Hemoglobin ≥9 g/dL.
  9. Serum triglyceride <300 mg/dL; serum cholesterol < 350 mg/dL.
  10. Male or non-pregnant and non-breast feeding female:

    • Females of child-bearing potential must agree to use effective contraception without interruption from 28 days prior to starting IP and while on study medication and have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment.
    • Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, even if he has undergone a successful vasectomy.
  11. Life expectancy of >3 months, as determined by the investigator.
  12. Ability to understand and sign informed consent.
  13. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.

Exclusion Criteria:

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Patients with lymphangioleiomyomatosis (LAM) are excluded.
  2. Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A patient with controlled and asymptomatic CNS metastases may participate in this study. As such, the patient must have completed any prior treatment for CNS metastases ≥28 days (including radiotherapy and/or surgery) prior to start of treatment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
  3. Active gastrointestinal bleeding, if transfusion dependent.
  4. Pre-existing thyroid abnormality is allowed provided thyroid function can be controlled with medication.
  5. Uncontrolled serious medical or psychiatric illness. Patients with a "currently active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and postoperative PSA <0.5 ng/mL), or other adequately treated carcinoma-in-situ are ineligible. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥1 year).
  6. Liver-directed therapy within 2 months of enrollment. Prior treatment with radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial embolization (with or without chemotherapy) or cyrotherapy/ablation) is allowed if these therapies did not affect the areas of measurable disease being used for this protocol.
  7. Recent infection requiring systemic anti-infective treatment that was completed

    ≤14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).

  8. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.
  9. Unstable coronary artery disease or myocardial infarction during preceding 6 months.
  10. Receiving any concomitant antitumor therapy.
  11. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
  12. The use of certain medications and illicit drugs within 5 half-lives or 28 days, whichever is shorter prior to the first dose of study drug and for the duration of the study will not be allowed.
  13. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to receiving the first dose of ABI-009.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02494570

Layout table for location information
United States, California
Stanford University Medical Center
Palo Alto, California, United States, 94304
Sarcoma Oncology Research Center
Santa Monica, California, United States, 90403
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Missouri
Washington University School of Medicine - Siteman Cancer Center
Saint Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, United States, 27710
United States, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Aadi Bioscience, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aadi Bioscience, Inc. Identifier: NCT02494570    
Other Study ID Numbers: PEC001
FD005749 ( Other Grant/Funding Number: FDA-OOPD )
AMPECT ( Other Identifier: Aadi )
First Posted: July 10, 2015    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type